Supriya Lifescience
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Supriya Lifescience is navigating a pivotal transition from a traditional API manufacturer to a comprehensive CDMO/CMO partner, as highlighted by management's focus on expanding its capabilities and product offerings. The company aims to achieve INR 1,000 crores in revenue for FY27, supported by strategic investments in its Patalganga and Ambernath facilities, which are expected to enhance its presence in regulated markets. Despite facing temporary headwinds such as water shortages and regulatory challenges, management remains optimistic about the long-term growth trajectory, underpinned by a robust R&D pipeline and a shift towards higher-value manufacturing partnerships. Vista's financial outlook reflects a cautious stance, anticipating moderating revenue growth and margin pressures, with a fair valuation aligned with intrinsic value. The industry context remains favorable, driven by increasing global demand for pharmaceutical products and the emergence of Indian CDMOs. However, potential regulatory impacts and raw material supply constraints pose risks. Over the next 12-24 months, key opportunities include expanding into new markets and product lines, while watchpoints include execution risks related to regulatory approvals and the need to manage inventory effectively
Why We Like This Stock
- Management's strategic shift towards CDMO services is expected to enhance revenue streams and market positioning
- A robust R&D pipeline and planned facility expansions are likely to unlock new growth opportunities in regulated markets
- The overall industry dynamics favor growth, with increasing global demand for pharmaceutical products
Things To Watch Out For
- Moderating revenue growth and margin pressures may impact short-term financial performance
- Execution risks related to regulatory approvals and inventory management could hinder operational efficiency
- Potential raw material supply constraints and geopolitical factors may pose challenges to sustained growth
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 570 | 696 | 828 | 826 | 941 |
| Profit Before Tax (Cr.) | 166 | 248 | 275 | 242 | 286 |
| PBT Margin | 29.1% | 35.6% | 33.2% | 29.3% | 30.4% |
| Net Profit (Cr.) | 128 | 192 | 213 | 187 | 222 |
| Earnings Per Share | 16.0 | 23.8 | 26.5 | 23.3 | 27.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Deven Choksey | ► Accumulate | 841 | 17-Aug-2026 |
| Choice Equity | ▲ Buy | 1,030 | 29-May-2026 |
Company Overview
Show Company Profile
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.